All News
Bimekizumab's Favorable Safety Profile in Psoriasis
A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.
Read Article
RNL 2022: Psoriatic Arthritis Advances
Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.
This webinar presented exerpts from these lectures along with audience Q & A
Read Article
Making You the Expert of You! (Smart Rules for Patients)
You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.
Read Article
$30 Billion and Counting (4.29.2022)
Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.
Read Article
We had a great TNR this week. Playback now available in case you missed it.
This webinar presented excerpts from these lectures along with Q & A
Psoriatic Arthritis Guidelines
Drug Targeting in PsA
PsA Registries and Real World Data
https://t.co/al17KLQm0j https://t.co/O4SvMU37Lg
Links:
Dr. John Cush RheumNow ( View Tweet)
Making You the Expert of You! (Smart Rules for Patients)
You’ve scheduled an appointment with your medical provider - how do you make the most of it?
https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3
Links:
Dr. John Cush RheumNow ( View Tweet)
Interested in what we covered in the month of April? You can find all our PsA content at the link below. What was your biggest takeaway from our PsA All the Way campaign?
https://t.co/hl0HKggULj https://t.co/O1QMibJ4qA
Links:
Dr. John Cush RheumNow ( View Tweet)
TOMORROW! Register for our 5/10 Tuesday Night Rheumatology on PsA Advances.
This webinar will feature highlights from:
PsA Guidelines
Arthur Kavanaugh, MD
Drug Targeting in PsA
Bruce Kirkham, MD
PsA Registries and Real World Data
Alexis Ogdie, MD
https://t.co/0fNuHz6wVy https://t.co/KssNJ41Wqz
Links:
Dr. John Cush RheumNow ( View Tweet)
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/U5wAQdWLdC https://t.co/QfoaogDeun
Links:
Dr. John Cush RheumNow ( View Tweet)
Large Korean population study compares pts w/ palmoplantar psoriasis vs psoriasis and PPP pts have more risk for ankylosing spondylitis (aOR 1.37) & Graves dz (aOR 1.4) but lower risk for PsA (aOR 0.54), SLE (0.67); Sjögren (0.70); vitiligo (0.53) https://t.co/0fv2vnFBPf https://t.co/PJMagIeZ2F
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 17 homeless RA or PsA pts - less clinic access (80% vs 91%), more ED use (20 vs 5), less DMARDs (43% vs 100%), more steroids (29% vs 0%); 83% unable to work due to health. Greatest need - dental , PT, knee surgery, employment & housing https://t.co/VHnTR0MTkr https://t.co/JDZTELz2qB
Links:
Dr. John Cush RheumNow ( View Tweet)
There is 1.4 million transgender persons in the US. ACP has published a guideline "Care of the Transgender Patient" addressing health disparities, certain cancers, substance abuse, mental health conditions, infections, and chronic diseases. https://t.co/AoBeOzv9YH https://t.co/jKabVELPxH
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 13 European registries on durability/effect of interleukin-17 (IL-17) inhibition with secukinumab: among 2,017 PsA on secukinumab, retention rates were 86% and 76% at 6 and 12 mos, with 12 mo remission rate of 11% to 16% https://t.co/03sJBSbUy6
Links:
Dr. John Cush RheumNow ( View Tweet)
Neural networks of high-res quantitative CT (HR-pQCT) scans allowed for 3D imaging of MCP2 to differentiate normals from #RA & #PsA. 932 of 617 ppts correct AuROC for HC 82%, RA 75%, PsA 68%. UA pts read as 86% RA,11% PsA, & 3% HC https://t.co/wSQgllYgug https://t.co/yA6g55SpeC
Links:
Dr. John Cush RheumNow ( View Tweet)
Thanks so much to all who contributed to April's PsA All the Way campaign on RheumNow. You can find all our PsA content at the link below. Did you learn anything new about PsA from our coverage?
https://t.co/Mo7Yf2cu4i https://t.co/LvpuLtF4Mv
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatologic diagnosis through hand exam by Dr. Sarah Chung @ACPinternists #rheumatology #rheumtwitter #MedEd #rheumatoidarthritis #BJHM #Hospitalmedicine #IM2022 #MedTwitter 👇🏽 https://t.co/qR4zNa4NcX
Brown Journal of Hospital Medicine BrownJHM ( View Tweet)
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/NiPTbknD57 https://t.co/HOC2Bev4R6
Links:
Dr. John Cush RheumNow ( View Tweet)
We completed a whole month of super-charged, focused coverage & education on #PsA.THANKS to the many mavens who contributed! In PSA - "Unless someone like you cares a whole awful lot, nothing is going to get better. It’s not." -Dr. Seuss, The Lorax https://t.co/Y58klwbS4V https://t.co/f2pnuypwyr
Links:
Dr. John Cush RheumNow ( View Tweet)
Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion about two important studies.
https://t.co/RjFRFt6oJQ https://t.co/zOxCDC1atS
Links:
Dr. John Cush RheumNow ( View Tweet)
Perplexing Oligoarthritis, +FHx, But no psoriasis
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/ljZ1cStNTy https://t.co/8RMFFWjDEP
Links:
Dr. John Cush RheumNow ( View Tweet)
